%0 Journal Article
%T A real
%A Amy L Phillips
%A Chris M Kozma
%A James D Bowen
%A Megan M Grosso
%J Multiple Sclerosis Journal
%@ 2055-2173
%D 2018
%R 10.1177/2055217318819031
%X Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFN¦Â-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide). Patients from an administrative claims database (1 Jan 2012¨C31 Dec 2015) were selected if they: were 18¨C63 years old; had an MS diagnosis; had newly initiated sc IFN¦Â-1a, dimethyl fumarate, fingolimod, or teriflunomide (first claim£¿=£¿index); had no evidence of DMD 12-months pre-index; and had 12-month eligibility pre- and post-index. Relapse was defined as an MS-related inpatient stay, emergency room visit, or outpatient visit with a corticosteroid prescription£¿¡À£¿7 days. Outcomes were evaluated using logistic regression and generalized linear models. A total of 4475 patients met inclusion criteria: 21.9% sc IFN¦Â-1a, 51.0% dimethyl fumarate, 19.7% fingolimod, 7.4% teriflunomide. Teriflunomide patients had 1.357 (95% CI 1.000, 1.831; p£¿=£¿0.0477) greater odds of 1-year relapse than sc IFN¦Â-1a patients. Estimated mean all-cause 1-year costs were higher after fingolimod (US$72,376) v. sc IFN¦Â-1a initiation (US$65,408; p£¿<£¿0.0001). Non-DMD costs were not significantly different. Patients initiating sc IFN¦Â-1a had better relapse outcomes v. teriflunomide, and lower all-cause costs v. fingolimod
%K Multiple sclerosis
%K disease-modifying drugs
%K retrospective database
%K relapse
%K cost
%K resource use
%U https://journals.sagepub.com/doi/full/10.1177/2055217318819031